Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. - Wikidata - awgldk - TriplyDB

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial.

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial.

http://www.wikidata.org/entity/Q34545862

about

Surgical management of localised renal cell carcinoma Surgical management of localised renal cell carcinoma Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy Immunotherapy for colorectal cancer Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma Sunitinib in the treatment of metastatic renal cell carcinoma Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?Immunotherapy for metastatic renal cell carcinoma.Renal cell cancer: overview of the current therapeutic landscape.Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients Breast cancer vaccines: a clinical reality or fairy tale?Is cancer vaccination feasible at older age?A modified adrenal gland-sparing surgery based on retroperitoneal laparoscopic radical nephrectomy.Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.Adjuvant therapy for renal cell carcinoma: past, present, and future Strategies for cancer vaccine development.DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown.Use of tumour-responsive T cells as cancer treatment.Everolimus - a new approach in the treatment of renal cell carcinoma Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine Recent advances in cancer vaccines: an overview.Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.Systemic adjuvant therapies in renal cell carcinoma Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles.Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Vaccination immunotherapy--an update.Advances in immune-based therapies of renal cell carcinoma.Cytokine and vaccine therapy of kidney cancer.Best Practice No 180. Nephrectomy for renal tumour; dissection guide and dataset.Regulators of apoptosis: suitable targets for immune therapy of cancer.Therapeutic approaches in metastatic renal cell carcinoma.What's new in the treatment of metastatic kidney cancer?Autologous tumor lysate/Bacillus Calmette-Guérin immunotherapy as an adjuvant to conventional breast cancer therapy T cell-mediated immunotherapy of metastases: state of the art in 2005.Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options.

P2860

Q24186058-545C7C45-1911-4553-9D2C-3EDEE0EDB894 Q24236818-4F4835C2-10C8-4B4C-93D4-C4A3A7CFA679 Q26991589-9BE53227-7586-42FD-B278-52969DD67CD6 Q27016032-089A0F89-8905-40B3-95D8-C061561BE7CB Q27021837-AAEBCD91-85E4-4F2A-BB35-85041C5065E9 Q27025873-E977EF7A-2683-46B4-8D5A-86D0BA6D494B Q28072057-0BAAC580-D7ED-4A8B-AC63-EDF64895562E Q28301672-35E7B781-D1C7-4051-A573-A73E1D0B1B2D Q30234458-44A509C5-460C-4D35-AD76-B3AEAA90CE32 Q30248354-107A2D85-92C4-4531-96D9-1A33D2F78BDC Q30313444-BAA33D25-AAAF-4F58-9C57-9E483B83037D Q30351838-0AFC558C-412C-4A6B-8F1A-F759EC3AF2F4 Q33739907-04A05B84-707E-42E1-BDC7-78C0FD54BA71 Q33775477-696AE172-2435-49EF-9F7A-557C4E72E8CB Q33843677-D9F34DD6-F04A-4075-8F7A-5418653B7546 Q33858807-4A2C1A29-8E7E-45A6-ADB6-E6F643C65530 Q33886261-BA1EA4F1-33A6-432B-925E-3F1E20DD2BDA Q34005127-61D5C4F2-8326-4852-9203-5E055E895DDB Q34038338-9AA2DA10-F633-42F0-BFD1-EFC9EF74C0C0 Q34160434-38E21E70-E875-4728-8E90-18E122B96725 Q34285656-EA0766EB-C464-416E-AADD-64BD8505F727 Q34417931-D08A4093-3204-49F1-9A21-1CDB5FBEBA0A Q34555854-5A5772FE-B205-42B5-A773-00F20761470A Q34675774-5BD8C706-BF7E-470B-85B1-A6923B6EC400 Q34882348-404AD2C9-2CE1-48EB-8EFE-C1BB3CA194EA Q35294382-5AB6A346-F953-4EFA-9273-B0A8EA272C07 Q35569322-3B5DF3E5-BE46-4A79-92F7-EEF38CCFA8DF Q35653886-6143C554-3383-4D1C-91AC-CF4827E6C171 Q35799377-21C98C18-E3F4-46FB-8BD8-41B213A7BDEA Q35799695-46786B23-25F4-483C-AE76-8DABBA7E674A Q35851700-1A53161E-2746-4948-A3CC-6B5AB8BE0DF3 Q35987770-DDD18B8B-0DA8-4676-8DBD-D20367D2B293 Q35987775-E8D121AE-92F3-4D5D-8EB8-DB95B1178660 Q35995717-95F2844F-72FE-4839-A1D2-A5D92A409739 Q36111911-8579DFDE-6795-4395-91F1-8A0D9BD33641 Q36118589-1ED2FCAA-7F29-4B48-84AB-AA1D57ECC003 Q36126876-92C029B3-8465-4C9E-87D8-06873EBADD11 Q36171703-7319EECB-210D-4C85-9AEE-3D5BBBDDEFE7 Q36210864-4A068F45-1E1B-4863-9609-EE02EFC9D5FE Q36232195-73F4F1D5-E706-4EC8-A2CF-0A0E66C4A322

P2860

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial.

http://www.wikidata.org/entity/Q34545862

description

2004 nî lūn-bûn

@nan

2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Adjuvant autologous renal tumo ...... , randomised controlled trial.

@ast

Adjuvant autologous renal tumo ...... , randomised controlled trial.

@en

Adjuvant autologous renal tumo ...... , randomised controlled trial.

@nl

type

label

Adjuvant autologous renal tumo ...... , randomised controlled trial.

@ast

Adjuvant autologous renal tumo ...... , randomised controlled trial.

@en

Adjuvant autologous renal tumo ...... , randomised controlled trial.

@nl

prefLabel

Adjuvant autologous renal tumo ...... , randomised controlled trial.

@ast

Adjuvant autologous renal tumo ...... , randomised controlled trial.

@en

Adjuvant autologous renal tumo ...... , randomised controlled trial.

@nl

P1433

Q34545862-197CFC3B-C8C7-4455-8458-EA16ABE35FEB

P1476

Q34545862-3FBC92DA-2B65-4053-945D-9DCD8511F56A

P2093

Q34545862-33E179EB-8C52-435A-80F6-E588F2F51803

Q34545862-6D133773-5CF6-4C3D-A0D1-A9C2F0136F4E

Q34545862-7E4CDC9A-2B14-47FF-873F-D09F7FC7664F

Q34545862-A835E52D-17DD-4E9C-92BA-8B4BF5E869D0

Q34545862-B66466AB-9C84-4FD6-B057-C24457CE53EE

Q34545862-BE347821-A0E6-4767-ACA7-6206BC89BF65

Q34545862-D4615D94-671E-4069-959B-24302C6B334F

Q34545862-F1421A70-EEAC-4021-9D78-07AFDFA746A6

Q34545862-F280824D-29A0-4E54-9C08-200592C5FE77

Q34545862-FB93B69F-D43C-470E-B0B3-2887DBBBE7CA

P304

Q34545862-1842E0C2-921C-4D2D-9F03-5914B3889371

P31

Q34545862-1A87D63F-367C-475B-B1F0-CF8E0C6D5A57

P356

Q34545862-20A56663-CB5A-4A5D-8050-47BC25C524D9

P407

Q34545862-D06FD308-C3D5-4BF4-9040-48FBD37027F9

P433

Q34545862-F78B0482-1058-4683-80CB-B9B0A82E4BEA

P478

Q34545862-4755ACD4-AAAE-49F2-AB08-30068B294A59

P50

Q34545862-A574455F-E89A-459F-B8EC-EB0B4FB0867A

P577

Q34545862-D470DF00-524A-4A00-879F-81D5ACCC9DF8

P698

Q34545862-0E5E276A-9137-4D2F-9960-28C9A46B6D16

P921

Q34545862-B11912FE-C6EA-41BC-8519-F538B086B218

Q34545862-F5944C7E-F7A2-4D3B-82E1-5358755D11F7

P356

S0140-6736(04)15590-6

P1433

P1476

Adjuvant autologous renal tumo ...... , randomised controlled trial.

@en

P2093

Axel Richter

http://www.w3.org/2001/XMLSchema#string

Christian Doehn

http://www.w3.org/2001/XMLSchema#string

Dieter Jocham

http://www.w3.org/2001/XMLSchema#string

Dirk Fahlenkamp

http://www.w3.org/2001/XMLSchema#string

Eberhard Schmitt

http://www.w3.org/2001/XMLSchema#string

Günther Zakrzewski

http://www.w3.org/2001/XMLSchema#string

Jörn von Wietersheim

http://www.w3.org/2001/XMLSchema#string

Klaus Iwig

http://www.w3.org/2001/XMLSchema#string

Lothar Hoffmann

http://www.w3.org/2001/XMLSchema#string

Thomas Dannenberg

http://www.w3.org/2001/XMLSchema#string

P304

594-599

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(04)15590-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

9409

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P50

Jörn von Wietersheim

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14987883

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial